Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy

Open access

Abstract

The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now. Initially considered undruggable, recent advances have successfully broken the jinx through covalent inhibition that exploits the mutated cys12 in the switch II binding pocket (KRAS G12C). Though this approach has achieved some level of success, patients with mutations other than cys12 are still uncatered for. KRAS G12D is the most frequent KRAS mutated oncoprotein. It is only until recently, MRTX1133 has been discovered as a potential inhibitor of KRAS G12D. This study seeks to unravel the structural binding mechanism of MRTX1133 as well as identify potential drug leads of KRAS G12D based on structural binding characteristics of MRTX1133. It was revealed that MRTX1133 binding stabilizes the binding site by increasing the hydrophobicity which resultantly induced positive correlated movements of switches I and II which could disrupt their interaction with effector and regulatory proteins. Furthermore, MRTX1133 interacted with critical residues; Asp69 (− 4.54 kcal/mol), His95 (− 3.65 kcal/mol), Met72 (− 2.27 kcal/mol), Thr58 (− 2.23 kcal/mol), Gln99 (− 2.03 kcal/mol), Arg68 (− 1.67 kcal/mol), Tyr96 (− 1.59 kcal/mol), Tyr64 (− 1.34 kcal/mol), Gly60 (− 1.25 kcal/mol), Asp12 (− 1.04 kcal/mol), and Val9 (− 1.03 kcal/mol) that contributed significantly to the total free binding energy of − 73.23 kcal/mol. Pharmacophore-based virtual screening based on the structural binding mechanisms of MRTX1133 identified ZINC78453217, ZINC70875226 and ZINC64890902 as potential KRAS G12D inhibitors. Further, structural optimisations and biochemical testing of these compounds would assist in the discovery of effective KRAS G12D inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-22668-1

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of the approach applied to this study. First four sections indicate the characterization approach applied to MRTX1133, while rest of the sections depict the process of hit compounds identification.
Figure 1 Schematic diagram of the approach applied to this study. First four sections indicate the characterization approach applied to MRTX1133, while rest of the sections depict the process of hit compounds identification.CC BY · PubMed Central
Figure 2 Comparative stability and solvent accessibility surface area of the binding site of KRASG12D upon the binding of MRTX1133 and the holo protein. (A) Shows the RMSD plots of the C-a atoms of the binding site residues indicating MRTX1133 binding stabilized the residues (red) relative to the holo (black). (B) Shows the SASA plots of the binding site residues indicating a reduction in surface area availability upon MRTX1133 binding (red) relative to the holo protein (black). (C) Shows the hydrophobicity of the binding site. (D) Shows the solvent accessible of area of the binding site.
Figure 2 Comparative stability and solvent accessibility surface area of the binding site of KRASG12D upon the binding of MRTX1133 and the holo protein. (A) Shows the RMSD plots of the C-a atoms of the binding site residues indicating MRTX1133 binding stabilized the residues (red) relative to the holo (black). (B) Shows the SASA plots of the binding site residues indicating a reduction in surface area availability upon MRTX1133 binding (red) relative to the holo protein (black). (C) Shows the hydrophobicity of the binding site. (D) Shows the solvent accessible of area of the binding site.CC BY · PubMed Central
Figure 3 Cross-correlation matrices of the fluctuations of coordinates of C–a atoms of the switches around their mean positions during the 450 ns simulation. DCCM plots of switch I MRTX1133 complex (A), Switch I holo (A1), Switch II MRTX1133 complex (B), and (B1) Switch II holo protein. This indicates MRTX1133 complexing induced a more corelated movement. (C) KRAS structure showing switch I (black) and switch II (red).
Figure 3 Cross-correlation matrices of the fluctuations of coordinates of C–a atoms of the switches around their mean positions during the 450 ns simulation. DCCM plots of switch I MRTX1133 complex (A), Switch I holo (A1), Switch II MRTX1133 complex (B), and (B1) Switch II holo protein. This indicates MRTX1133 complexing induced a more corelated movement. (C) KRAS structure showing switch I (black) and switch II (red).CC BY · PubMed Central
Figure 4 2D interactions of MRTX1133 with KRASG12D binding site residues. Snapshots depicts interactions at 100 ns, 200 ns, 300 ns and 450 ns. MRTX1133 engages in varying interactions.
Figure 4 2D interactions of MRTX1133 with KRASG12D binding site residues. Snapshots depicts interactions at 100 ns, 200 ns, 300 ns and 450 ns. MRTX1133 engages in varying interactions.CC BY · PubMed Central
Figure 5 Per-residue decomposition analysis showing binding site residue energy contributions towards the complexing of MRTX1133. Electrostatic energy featured prominently towards the total free binding energy. (A) Shows the energy plots. (B) Shows the interacting residues.
Figure 5 Per-residue decomposition analysis showing binding site residue energy contributions towards the complexing of MRTX1133. Electrostatic energy featured prominently towards the total free binding energy. (A) Shows the energy plots. (B) Shows the interacting residues.CC BY · PubMed Central
Figure 6 A pharmacophore model of MRTX1133. (A) 2D illustration of MRTX1133 interacting with binding site residues after 450 ns MD simulation. (B) The selected pharmacophoric moieties in MRTX1133, which interacted with the most negative energy contributing binding site residues. (C) PRED plot highlighting only the total binding energy contributed by the selected active site residues.
Figure 6 A pharmacophore model of MRTX1133. (A) 2D illustration of MRTX1133 interacting with binding site residues after 450 ns MD simulation. (B) The selected pharmacophoric moieties in MRTX1133, which interacted with the most negative energy contributing binding site residues. (C) PRED plot highlighting only the total binding energy contributed by the selected active site residues.CC BY · PubMed Central
Figure 7 2D molecular interactions of MRTX1133 and selected compounds within the binding site of KRAS allosteric binding site. The selected compounds and MRTX1133 show similar interactions with the binding site residues suggesting the selected compounds have the potential to elicit similar therapeutic effects.
Figure 7 2D molecular interactions of MRTX1133 and selected compounds within the binding site of KRAS allosteric binding site. The selected compounds and MRTX1133 show similar interactions with the binding site residues suggesting the selected compounds have the potential to elicit similar therapeutic effects.CC BY · PubMed Central
Figure 8 (A) Superimposition of KRASG12D complexed with ZINC78453217, ZINC70875226, ZINC64890902 and MRTX1133. Insert shows the binding orientation of each inhibitor at 100 ns, 300 ns, and 450 ns. (B) Comparative inhibitor stability plots using RMSD metrics for ZINC78453217, ZINC70875226, ZINC64890902 and MRTX1133. (C) Comparative inhibitor SASA plots of ZINC78453217, ZINC70875226, ZINC64890902 and MRTX1133.
Figure 8 (A) Superimposition of KRASG12D complexed with ZINC78453217, ZINC70875226, ZINC64890902 and MRTX1133. Insert shows the binding orientation of each inhibitor at 100 ns, 300 ns, and 450 ns. (B) Comparative inhibitor stability plots using RMSD metrics for ZINC78453217, ZINC70875226, ZINC64890902 and MRTX1133. (C) Comparative inhibitor SASA plots of ZINC78453217, ZINC70875226, ZINC64890902 and MRTX1133.CC BY · PubMed Central
Figure 9 Principal component analysis of the motions of the selected compounds at the allosteric binding site of KRASG12D.
Figure 9 Principal component analysis of the motions of the selected compounds at the allosteric binding site of KRASG12D.CC BY · PubMed Central
Figure 10 2D interactions of hit compounds with KRASG12D binding site residues. Snapshots depicts interactions at 100 ns, 200 ns, 300 ns and 450 ns. (A) Shows ZINC78453217 interactions with the binding site residues. (A1) Shows ZINC70875226 interaction with the binding site residues. (A2) Shows ZINC64890902 interactions with the binding site interactions.
Figure 10 2D interactions of hit compounds with KRASG12D binding site residues. Snapshots depicts interactions at 100 ns, 200 ns, 300 ns and 450 ns. (A) Shows ZINC78453217 interactions with the binding site residues. (A1) Shows ZINC70875226 interaction with the binding site residues. (A2) Shows ZINC64890902 interactions with the binding site interactions.CC BY · PubMed Central
Figure 11 Comparative RMSD, RMSF and RoG plots of the hit compounds, MRTX1133 and unbound (holo) KRASG12D protein. (A) Shows the binding site RMSD elicited by the binding of the hit compounds. (B) Depicts the global stability of KRASG12D upon compounds binding. (C) Shows the residual fluctuations exhibited by the global protein residues during the simulation period. Highlights (deep yellow) show the switches regions. (D) Shows the RoG exhibited by the global protein. The bound conformations are contrasted to the unbound (Holo).
Figure 11 Comparative RMSD, RMSF and RoG plots of the hit compounds, MRTX1133 and unbound (holo) KRASG12D protein. (A) Shows the binding site RMSD elicited by the binding of the hit compounds. (B) Depicts the global stability of KRASG12D upon compounds binding. (C) Shows the residual fluctuations exhibited by the global protein residues during the simulation period. Highlights (deep yellow) show the switches regions. (D) Shows the RoG exhibited by the global protein. The bound conformations are contrasted to the unbound (Holo).CC BY · PubMed Central
Figure 12 Most promising inhibitors of KRASG12D.
Figure 12 Most promising inhibitors of KRASG12D.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Research works printed but not linked: 1

  1. Schweizer, L. & Mueller, L. protein conformational dynamics and signaling in evolution and pathophysiology. In Arey Pharmacology and Therapeutics 209–249 (Academic Press, San Diego, 2014).

Cited by

See all 96

Metadata

Authors
Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J.
Affiliations
  • University of KwaZulu-Natal (ZA)
  • Majmaah University (SA)
Corresponding author
Rudrapal, Mithun
Venue
Scientific Reports
Published
2022-10-22
Volume
12
Issue
1
Pages
17796-17796
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4307138949
Cited by
93
References
66
Citations by year
2026: 13 · 2025: 21 · 2024: 41 · 2023: 18
FWCI
6.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
MRTX1133, KRAS G12D, KRAS inhibitors, covalent inhibition, binding free energy, hydrophobic stabilization, pharmacophore-based virtual screening, lead compound identification, cancer therapy
MeSH terms
Binding Sites, Humans, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. https://app.cochat.ai/papers/10.1038/s41598-022-22668-1
The paper
Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J. (2022). Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Scientific Reports. https://doi.org/10.1038/s41598-022-22668-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.